{"denoms":[{"counts":[{"groupId":"BG000","value":"156"},{"groupId":"BG001","value":"154"},{"groupId":"BG002","value":"154"},{"groupId":"BG003","value":"129"},{"groupId":"BG004","value":"230"},{"groupId":"BG005","value":"405"},{"groupId":"BG006","value":"1228"}],"units":"Participants"}],"groups":[{"description":"Participants in clinical response to golimumab at Week 6 of induction study C0524T16 (NCT00488774) or C0524T17 (NCT00487539) and randomized to placebo subcutaneous injection matching to golimumab administered every 4 weeks through Week 52 in the maintenance study C0524T18 (NCT00488631). Participants with loss of clinical response had their dose increased to golimumab 100 mg subcutaneous injection administered every 4 weeks through Week 52. For participants with dose adjustment, adverse events are presented from Week 0 up to the time of dose adjustment.","id":"BG000","title":"Golimumab Induction Responders (GLM-I-Rsp)-Placebo Maintenance"},{"description":"Participants in clinical response to golimumab at Week 6 of induction study C0524T16 (NCT00488774) or C0524T17 (NCT00487539) and randomized to golimumab 50 mg subcutaneous injection administered every 4 weeks through Week 52 in C0524T18 (NCT00488631). Participants with loss of clinical response were re-randomized to receive golimumab 50 mg or 100 mg subcutaneous injection administered every 4 weeks through Week 52. For participants with dose adjustment, adverse events are presented from Week 0 up to the time of dose increase.","id":"BG001","title":"GLM-I-Rsp-Golimumab 50 mg Maintenance"},{"description":"Participants in clinical response to golimumab at Week 6 of induction study C0524T16 (NCT00488774) or C0524T17 (NCT00487539) and randomized to golimumab 100 mg subcutaneous injection administered every 4 weeks through Week 52 in maintenance study C0524T18 (NCT00488631). Participants with loss of clinical response were re-randomized to receive golimumab 100 mg or 200 mg subcutaneous injection administered every 4 weeks through Week 52 (prior to protocol amendment 3). For participants with dose adjustment, adverse events are presented from Week 0 up to the time of dose increase.","id":"BG002","title":"GLM-I-Rsp-Golimumab 100 mg Maintenance"},{"description":"Participants in clinical response to placebo at Week 6 of an induction study C0524T16 (NCT00488774) or C0524T17 (NCT00487539) and received placebo subcutaneous injection matching to golimumab every 4 weeks through Week 52 in maintenance study C0524T18 (NCT00488631); not randomized. Participants with loss of clinical response had their dose increased to golimumab 100 mg subcutaneous injection administered every 4 weeks through Week 52. For participants with dose adjustment, adverse events are presented from Week 0 up to the time of dose adjustment.","id":"BG003","title":"Placebo Induction Responders (PBO-I-Rsp)-Placebo Maintenance"},{"description":"Participants not in clinical response to placebo at Week 6 of induction study C0524T16 (NCT00488774) or C0524T17 (NCT00487539) and received golimumab 100 mg subcutaneous injection administered every 4 weeks through Week 52 in maintenance study C0524T18 (NCT00488631); not randomized.","id":"BG004","title":"PBO-I-nonRsp-Golimumab 100 mg Maintenance"},{"description":"Participants not in clinical response to golimumab at Week 6 of induction study C0524T16 (NCT00488774) or C0524T17 (NCT00487539) and received golimumab 100 mg subcutaneous injection administered every 4 weeks through Week 52 in maintenance study C0524T18 (NCT00488631); not randomized.","id":"BG005","title":"GLM-I-nonRsp-Golimumab 100 mg Maintenance"},{"description":"Total of all reporting groups","id":"BG006","title":"Total"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","spread":"14.05","value":"40.2"},{"groupId":"BG001","spread":"13.84","value":"41.4"},{"groupId":"BG002","spread":"13.11","value":"39.1"},{"groupId":"BG003","spread":"13.27","value":"38"},{"groupId":"BG004","spread":"12.67","value":"40.3"},{"groupId":"BG005","spread":"13.6","value":"41.2"},{"groupId":"BG006","spread":"13.44","value":"40.3"}]}]}],"dispersionType":"STANDARD_DEVIATION","paramType":"MEAN","title":"Age, Continuous","unitOfMeasure":"years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"81"},{"groupId":"BG001","value":"77"},{"groupId":"BG002","value":"65"},{"groupId":"BG003","value":"68"},{"groupId":"BG004","value":"99"},{"groupId":"BG005","value":"138"},{"groupId":"BG006","value":"528"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"75"},{"groupId":"BG001","value":"77"},{"groupId":"BG002","value":"89"},{"groupId":"BG003","value":"61"},{"groupId":"BG004","value":"131"},{"groupId":"BG005","value":"267"},{"groupId":"BG006","value":"700"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"}]}